Weekly Analysts’ Ratings Changes for Regeneron Pharmaceuticals (REGN)

Several analysts have recently updated their ratings and price targets for Regeneron Pharmaceuticals (NASDAQ: REGN):

• 10/23/2024 – Regeneron Pharmaceuticals had its price target lowered by analysts at Barclays PLC from $1,220.00 to $1,080.00. They now have an “overweight” rating on the stock.
• 10/23/2024 – Regeneron Pharmaceuticals had its “neutral” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $1,015.00 price target on the stock.
• 10/22/2024 – Regeneron Pharmaceuticals was upgraded by analysts at StockNews.com from a “buy” rating to a “strong-buy” rating.
• 10/22/2024 – Regeneron Pharmaceuticals had its price target lowered by analysts at Wells Fargo & Company from $1,200.00 to $1,050.00. They now have an “overweight” rating on the stock.
• 10/22/2024 – Regeneron Pharmaceuticals had its “outperform” rating reaffirmed by analysts at Royal Bank of Canada. They now have a $1,260.00 price target on the stock.
• 10/16/2024 – Regeneron Pharmaceuticals had its price target lowered by analysts at Truist Financial Co. from $1,200.00 to $1,137.00. They now have a “buy” rating on the stock.
• 10/9/2024 – Regeneron Pharmaceuticals was upgraded by analysts at StockNews.com from a “buy” rating to a “strong-buy” rating.
• 10/4/2024 – Regeneron Pharmaceuticals had its price target raised by analysts at Royal Bank of Canada from $1,252.00 to $1,260.00. They now have an “outperform” rating on the stock.
• 9/25/2024 – Regeneron Pharmaceuticals was downgraded by analysts at StockNews.com from a “strong-buy” rating to a “buy” rating.
• 9/24/2024 – Regeneron Pharmaceuticals had its price target lowered by analysts at Royal Bank of Canada from $1,282.00 to $1,252.00. They now have an “outperform” rating on the stock.
• 9/24/2024 – Regeneron Pharmaceuticals had its “outperform” rating reaffirmed by analysts at BMO Capital Markets. They now have a $1,300.00 price target on the stock.
• 9/24/2024 – Regeneron Pharmaceuticals had its “market perform” rating reaffirmed by analysts at Leerink Partners. They now have a $1,077.00 price target on the stock, down previously from $1,175.00.
• 9/24/2024 – Regeneron Pharmaceuticals was downgraded by analysts at Leerink Partnrs from a “strong-buy” rating to a “hold” rating.
• 9/24/2024 – Regeneron Pharmaceuticals had its “buy” rating reaffirmed by analysts at Truist Financial Co.. They now have a $1,200.00 price target on the stock.
• 9/23/2024 – Regeneron Pharmaceuticals had its “overweight” rating reaffirmed by analysts at Wells Fargo & Company. They now have a $1,200.00 price target on the stock.
• 9/17/2024 – Regeneron Pharmaceuticals had its “outperform” rating reaffirmed by analysts at Royal Bank of Canada. They now have a $1,282.00 price target on the stock.
• 9/16/2024 – Regeneron Pharmaceuticals had its “neutral” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $1,015.00 price target on the stock.
• 9/10/2024 – Regeneron Pharmaceuticals was upgraded by analysts at StockNews.com from a “buy” rating to a “strong-buy” rating.
• 9/9/2024 – Regeneron Pharmaceuticals had its “neutral” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $1,015.00 price target on the stock.
• 9/5/2024 – Regeneron Pharmaceuticals had its “outperform” rating reaffirmed by analysts at Royal Bank of Canada. They now have a $1,250.00 price target on the stock.
• 9/2/2024 – Regeneron Pharmaceuticals was downgraded by analysts at StockNews.com from a “strong-buy” rating to a “buy” rating.

Regeneron Pharmaceuticals Trading Down 2.2 %

NASDAQ:REGN opened at $941.39 on Thursday. Regeneron Pharmaceuticals, Inc. has a 12 month low of $769.19 and a 12 month high of $1,211.20. The company has a current ratio of 5.44, a quick ratio of 4.62 and a debt-to-equity ratio of 0.10. The firm’s 50 day moving average is $1,098.29 and its 200 day moving average is $1,040.67. The stock has a market capitalization of $103.73 billion, a PE ratio of 27.81, a price-to-earnings-growth ratio of 3.40 and a beta of 0.12.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $8.93 by $2.63. The firm had revenue of $3.55 billion for the quarter, compared to analyst estimates of $3.38 billion. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. The business’s revenue was up 12.3% on a year-over-year basis. During the same period in the previous year, the company posted $8.79 earnings per share. Sell-side analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.6 earnings per share for the current year.

Insider Activity at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, VP Jason Pitofsky sold 487 shares of the stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $1,070.00, for a total transaction of $521,090.00. Following the completion of the transaction, the vice president now owns 4,204 shares in the company, valued at $4,498,280. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other news, VP Jason Pitofsky sold 487 shares of Regeneron Pharmaceuticals stock in a transaction on Wednesday, August 7th. The stock was sold at an average price of $1,070.00, for a total value of $521,090.00. Following the completion of the transaction, the vice president now directly owns 4,204 shares in the company, valued at approximately $4,498,280. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Christopher R. Fenimore sold 5,680 shares of the business’s stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the sale, the chief financial officer now owns 15,305 shares in the company, valued at approximately $18,447,575.65. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.48% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Several hedge funds have recently bought and sold shares of REGN. Gateway Investment Advisers LLC increased its stake in Regeneron Pharmaceuticals by 13.7% in the 1st quarter. Gateway Investment Advisers LLC now owns 1,337 shares of the biopharmaceutical company’s stock worth $1,287,000 after acquiring an additional 161 shares during the last quarter. Wealthcare Advisory Partners LLC increased its position in shares of Regeneron Pharmaceuticals by 14.4% in the first quarter. Wealthcare Advisory Partners LLC now owns 294 shares of the biopharmaceutical company’s stock worth $283,000 after purchasing an additional 37 shares during the last quarter. Janiczek Wealth Management LLC increased its position in shares of Regeneron Pharmaceuticals by 20.1% in the first quarter. Janiczek Wealth Management LLC now owns 221 shares of the biopharmaceutical company’s stock worth $213,000 after purchasing an additional 37 shares during the last quarter. Wealth Enhancement Advisory Services LLC lifted its position in Regeneron Pharmaceuticals by 11.6% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 23,151 shares of the biopharmaceutical company’s stock valued at $22,283,000 after purchasing an additional 2,412 shares during the last quarter. Finally, 180 Wealth Advisors LLC purchased a new position in Regeneron Pharmaceuticals in the 1st quarter worth approximately $218,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.